Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.64
+0.14009.33%
Post-market: 1.670.0300+1.83%19:57 EST
Volume:2.92M
Turnover:4.76M
Market Cap:244.36M
PE:-0.70
High:1.68
Open:1.51
Low:1.51
Close:1.50
52wk High:2.64
52wk Low:0.5300
Shares:149.00M
Float Shares:105.00M
Volume Ratio:0.76
T/O Rate:2.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3306
EPS(LYR):-10.1929
ROE:-228.64%
ROA:-87.81%
PB:76.12
PE(LYR):-0.16

Loading ...

Palisade Bio to Present at Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Feb 05

Palisade Bio Director Donald Allen Williams Reports Acquisition of Common Shares

Reuters
·
Jan 22

BUZZ-Palisade Bio rises; bowel disease drug set for global conference spotlight

Reuters
·
Jan 16

BRIEF-Palisade Bio Announces Two Abstracts Selected For Poster Presentations At Leading Global Inflammatory Bowel Disease Conferences

Reuters
·
Jan 16

Palisade Bio Unveils Positive Phase 1a Results for Gut-Targeted Ulcerative Colitis Drug PALI-2108

Reuters
·
Jan 16

Director Donald Allen Williams Acquires Common Shares of Palisade Bio Inc

Reuters
·
Jan 14

Palisade Bio Initiated at Buy by B. Riley Securities

Dow Jones
·
Jan 09

B. Riley Initiates Palisade Bio at Buy With $7 Price Target

MT Newswires Live
·
Jan 09

Palisade Bio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $7

THOMSON REUTERS
·
Jan 09

Palisade Bio Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Jan 06

Palisade Bio Initiated at Buy by Clear Street

Dow Jones
·
Dec 31, 2025

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

GlobeNewswire
·
Dec 30, 2025

Palisade Bio Initiated at Overweight by Piper Sandler

Dow Jones
·
Dec 29, 2025

U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio

Reuters
·
Dec 29, 2025

Palisade Bio Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $25

THOMSON REUTERS
·
Dec 29, 2025

BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec

Reuters
·
Dec 02, 2025

Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development

THOMSON REUTERS
·
Dec 02, 2025

Palisade Bio price target raised to $8 from $2 at Maxim

TIPRANKS
·
Nov 12, 2025

Palisade Bio Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 29, 2025